ScripPatients with early Alzheimer’s disease, caregivers and doctors who may have been reluctant to try Eli Lilly’s Kisunla (donanemab) due to the risk of amyloid-related imaging abnormalities (ARIA) with
ScripBliss Biopharmaceutical (Hangzhou) (BlissBio), a Chinese developer of antibody-drug conjugates (ADCs), will rely on itself to advance BB-1701, a HER2-targeting ADC carrying the microtubule inhibitor e
Pink SheetEisai and Eli Lilly are to appeal against today’s final decision by England’s health technology assessment institute, NICE, to deny funding for their respective Alzheimer’s disease drugs – Leqembi and
ScripThe biggest upcoming catalysts for NewAmsterdam Pharma’s CETP inhibitor obicetrapib as a means for lowering low-density lipoprotein cholesterol (LDL-C) are regulatory submissions later this year based